Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
260.8 EUR | -21.19% | 0.00% | 0.00% |
11:54am | Truist Securities Raises Price Target on Genmab to $53 From $50, Maintains Buy Rating | MT |
06-03 | Genmab's Tisotumab Shows 'Encouraging' Antitumor Activity in Phase 2 Head, Neck Cancer Study | MT |
Sales 2024 * | 19.8B 2.89B 2.65B 3.95B | Sales 2025 * | 23.62B 3.44B 3.16B 4.71B | Capitalization | 126B 18.29B 16.81B 25.04B |
---|---|---|---|---|---|
Net income 2024 * | 4.68B 682M 627M 934M | Net income 2025 * | 6.61B 964M 886M 1.32B | EV / Sales 2024 * | 5.03 x |
Net cash position 2024 * | 25.92B 3.78B 3.47B 5.17B | Net cash position 2025 * | 32.36B 4.72B 4.33B 6.46B | EV / Sales 2025 * | 3.94 x |
P/E ratio 2024 * |
28.7
x | P/E ratio 2025 * |
20.6
x | Employees | 2,286 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.51% |
Latest transcript on Genmab A/S
1 day | -21.16% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 63 | 98-12-31 | |
Anthony Pagano
DFI | Director of Finance/CFO | 46 | 06-12-31 |
Anthony Mancini
COO | Chief Operating Officer | 53 | 20-03-22 |
Members of the board | Title | Age | Since |
---|---|---|---|
Deirdre Connelly
CHM | Chairman | 63 | 16-12-31 |
Director/Board Member | 73 | 03-10-31 | |
Rolf K. Hoffmann
BRD | Director/Board Member | 64 | 15-12-31 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+15.55% | 121B | |
+12.66% | 107B | |
-2.53% | 24.82B | |
+1.37% | 22.48B | |
-42.28% | 16.33B | |
-18.92% | 15.31B | |
+6.19% | 14.08B | |
+28.83% | 11.74B | |
+80.51% | 9.02B |
- Stock Market
- Equities
- GMAB Stock
- GE9 Stock